Trial Profile
Glycaemic control and quality of care in type 2 diabetes on NovoMix 30 [Insulin aspart/insulin protamine aspart] previously treated with Mixtard insulins
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 11 Jan 2017
Price :
$35
*
At a glance
- Drugs Insulin aspart/insulin protamine aspart (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 15 May 2009 Actual patient number (3495) added as reported by ClinicalTrials.gov.
- 15 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 May 2008 New trial record.